Psychometric Validation of the Psychosocial Assessment Tool in Caregivers of Pediatric Cancer Patients.

The reported mental health, economic and structural problems of pediatric cancer patients end up negatively affecting family functioning and the course of the disease; therefore, in the Mexican context it is necessary to have a valid, reliable and culturally relevant tool to identify psychosocial risks in children and adolescents with cancer. in order to develop strategies to address psychosocial needs. Objective: To determine the psychometric validation of the Mexican version of the Psychosocial Assessment Tool (PAT) for informal primary caregivers of pediatric cancer patients. Method: A study will be carried out with a prospective multicenter instrumental design of correlational scope and a non-probabilistic sampling will be used at the convenience of informal primary caregivers of pediatric cancer patients. The indices of relevance, writing and adequate language will be evaluated, in order to obtain content validity of each of the 68 items, using the Aiken V, reliability will be evaluated by calculating the Kuder-Richardson 20 coefficient to determine internal consistency and structural or construct validity will be evaluated by means of an exploratory factor analysis. Results: According to the guidelines for adaptation and validation of psychological instruments, the inventory will be translated into the original language (English - Spanish), the inventory will be backtranslated into the original language (Spanish - English), the evidence of content validity will be obtained by expert judges, and the evidence of construct validity and reliability indices of the inventory will be piloted and obtained with the white sample. Keywords: Pediatric patients, cancer, psychosocial risk, informal primary caregivers, pediatric oncology.

NCT Number	NCT07321392
Lead Sponsor	Aquí Nadie Se Rinde I.A.P.
Conditions	Pediatric Patients With Cancer, Informal Primary Caregivers
Enrollment	236 participants
Start Date	2025-12-10
Primary Completion	2026-03 (estimated)
Study Completion	2026-03 (estimated)
Updated on ClinicalTrials.gov	2026-03-31